Nipocalimab led to sustained MG-ADL and QMG improvements over 84 weeks with long-term IgG reduction in gMG patients. 45% of ...

J&J exhibited additional findings from the Vivacity-MG3 study, displaying that nipocalimab met its key secondary endpoint.

HOUSE, PA — Johnson & Johnson presented new data on its investigational treatment, nipocalimab, at the 2025 American Academy ...

If the FDA approves nipocalimab, the long-term data could form part of J&J’s pitch for the gMG market. The labels for ...

Johnson & Johnson announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label ...

Editor's notes: a. The open-label extension (OLE) interim analysis includes 60 weeks of open-label data, totalling 84 weeks for nipocalimab-treated participants, including 24 weeks from the ...

March 18, 2025 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD ...

Johnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, nipocalimab, for treating adult patients with moderate-to-severe Sjögren ...

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjögren's disease (SjD), an autoimmune condition that affects millions of people ...

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press release from Johnson & Johnson. The announcement comes 5 months after the ...

The additional analysis confirmed that patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their Myasthenia Gravis Activities of Daily Living (MG-ADL ...